Influencers’ Drug Promotions Pose Public Health Risks: JAMA

A new study published in JAMA Network Open highlights growing public health concerns over prescription drug promotion by social media influencers. The systematic review found that influencer-driven marketing frequently spreads misinformation, benefits from weak regulatory oversight, and leverages personal storytelling to increase persuasiveness, often making it difficult for audiences to recognize paid promotion.

Researchers conducted a systematic scoping review of 12 peer-reviewed articles examining influencer promotion of prescription drugs, including contraceptives, performance-enhancing medications, and other pharmaceuticals. They identified three major concerns:

1. Misinformation: Influencers often share content beyond their expertise, exaggerate benefits, and omit alternatives or risks, which may mislead audiences with low health literacy. Even some health professionals acting as influencers can unintentionally provide misleading guidance when commercial and professional roles overlap.
2. Weak Regulation: Current FDA and FTC guidance is outdated and inconsistently enforced. Sponsored content is frequently hard for audiences to identify, and international oversight is fragmented, leaving much influencer promotion unmonitored.
3. Persuasive Personal Narratives: Influencers frequently embed promotional content in personal or emotionally resonant stories, creating “parasocial” relationships where audiences perceive one-sided intimacy with the influencer. These narratives can reduce critical evaluation of the promoted medication and amplify the impact of misleading information.

The review noted high-profile examples, such as celebrity influencers promoting a migraine medication, as well as smaller-scale patient influencers endorsing prescription weight loss drugs. Studies also found that even unbranded posts framed as illness awareness could subtly encourage product use without clear disclosure.

The authors emphasize the urgent need for updated regulatory frameworks, standardized disclosure requirements, stronger platform accountability, and targeted digital literacy initiatives. They recommend proactive collaboration among regulators, researchers, and social media platforms to mitigate risks associated with influencer-driven pharmaceutical promotion.

While the evidence base remains limited and fragmented, the study concludes that emotionally compelling narratives, low audience health literacy, and insufficient transparency pose real risks to safe and informed medication use.